CUPID — A CONDOM MANUFACTURER TURNING INTO A HEALTH STORY!

Sometimes a small manufacturing business finds a much bigger market. Cupid is attempting exactly that — scaling healthcare exports while expanding its domestic consumer reach. 📊 Q1 FY27: EXPLOSIVE GROWTH 💰 Revenue: ₹154.7 crore, up 158.7% YoY. 🚀 Operating profit: ₹60.1 crore, up 264.7%. 📈 Net profit: ₹44.2 crore, up around 194% YoY. 🔥 WHAT COULD DRIVE THE NEXT LEG? ✅ Global healthcare exports: Cupid manufactures male and female condoms, lubricants and in-vitro diagnostic products, with customers across international markets. ✅ Capacity expansion: Its new Palava dual-polymer facility is designed to support substantial additional manufacturing capacity as operations scale. ✅ Domestic consumer opportunity: Wider distribution and stronger brand awareness could expand its presence in India's personal-care market. ✅ Raised FY27 guidance: Management raised its full-year revenue target to above ₹800 crore and net profit target to above ₹250 crore in its September business update. These are management targets, not guaranteed outcomes. ⚠️ WHAT COULD BREAK THE MOMENTUM? Rapid growth creates execution challenges. Investors should track capacity utilisation, customer concentration, export demand, working capital and whether profits convert into cash. Valuation is another major risk: after a substantial share-price rally, even strong business performance may not translate into equally strong future stock returns. 🎯 THE BOTTOM LINE Cupid combines a specialised healthcare-manufacturing business with ambitious growth targets and expanding capacity. The next test is turning exceptional growth into repeatable earnings, healthy cash flow and sustainable returns on capital.